© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Pyxis Oncology, Inc. (PYXS) stock declined over -2.35%, trading at $3.33 on NASDAQ, down from the previous close of $3.41. The stock opened at $3.42, fluctuating between $3.33 and $3.44 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | 3.38 | 3.44 | 3.33 | 3.33 | 563.43K |
| Sep 17, 2026 | 3.43 | 3.47 | 3.34 | 3.41 | 476.55K |
| Sep 16, 2026 | 3.34 | 3.42 | 3.32 | 3.34 | 639.84K |
| Sep 15, 2026 | 3.40 | 3.42 | 3.24 | 3.33 | 489.31K |
| Sep 14, 2026 | 3.21 | 3.52 | 3.21 | 3.43 | 699.48K |
| Sep 11, 2026 | 3.31 | 3.42 | 3.07 | 3.21 | 1.13M |
| Sep 10, 2026 | 3.42 | 3.44 | 3.18 | 3.27 | 738.44K |
| Sep 09, 2026 | 3.48 | 4.12 | 3.13 | 3.38 | 4.34M |
| Sep 08, 2026 | 4.00 | 4.15 | 3.85 | 3.89 | 1.3M |
| Sep 04, 2026 | 3.53 | 4.05 | 3.52 | 3.89 | 2.23M |
| Sep 03, 2026 | 3.71 | 3.74 | 3.45 | 3.57 | 812.15K |
| Sep 02, 2026 | 3.45 | 3.77 | 3.44 | 3.75 | 726.73K |
| Sep 01, 2026 | 3.24 | 3.57 | 3.18 | 3.44 | 590.16K |
| Aug 31, 2026 | 3.20 | 3.28 | 3.05 | 3.24 | 466.15K |
| Aug 28, 2026 | 3.32 | 3.38 | 3.20 | 3.23 | 211.99K |
| Aug 27, 2026 | 3.31 | 3.37 | 3.23 | 3.32 | 396.72K |
| Aug 26, 2026 | 3.03 | 3.36 | 3.00 | 3.34 | 633K |
| Aug 25, 2026 | 2.96 | 3.09 | 2.94 | 3.06 | 422.1K |
| Aug 24, 2026 | 3.02 | 3.07 | 2.83 | 2.96 | 837.42K |
| Aug 21, 2026 | 3.15 | 3.21 | 3.02 | 3.08 | 682.01K |
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
| Employees | 56 |
| Beta | 1.34 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |